Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $41
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $37 to $41.
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $37 to $41.